Systemic Therapy in Advanced Pleomorphic Liposarcoma: a Comprehensive Review.
Chemotherapy
Liposarcoma
Pleomorphic
Sarcoma
Soft tissue
Journal
Current treatment options in oncology
ISSN: 1534-6277
Titre abrégé: Curr Treat Options Oncol
Pays: United States
ID NLM: 100900946
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
accepted:
24
09
2023
medline:
14
11
2023
pubmed:
16
10
2023
entrez:
16
10
2023
Statut:
ppublish
Résumé
The therapeutic approach of pleomorphic liposarcoma (PLPS), a rare high-grade subgroup of soft tissue sarcoma, is commonly extrapolated from the management of other LPS subtypes. Only published retrospective data on PLPS currently serve as a guide for oncologists without clear recommendations or specific guidelines. In the advanced setting, specific systemic therapy such as eribulin and trabectedin showed promising activity in comparison to conventional therapy (doxorubicin- and gemcitabine-based protocols), which currently remains the current standard of care at initial stages of the disease. The better understanding of soft tissue sarcoma (STS) pathophysiology and disease course has led to the development of adapted clinical trial designs for rare STS histotypes with specific treatment approach.
Identifiants
pubmed: 37843627
doi: 10.1007/s11864-023-01139-3
pii: 10.1007/s11864-023-01139-3
doi:
Substances chimiques
Trabectedin
ID0YZQ2TCP
Doxorubicin
80168379AG
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1598-1613Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.